公开(公告)号：US08541448B2

公开(公告)日：2013-09-24

申请号：US13172394

申请日：2011-06-29

申请人： Dominique Charmot ,  Jeffrey W. Jacobs ,  Michael Robert Leadbetter ,  Marc Navre ,  Christopher Carreras ,  Noah Bell

发明人： Dominique Charmot ,  Jeffrey W. Jacobs ,  Michael Robert Leadbetter ,  Marc Navre ,  Christopher Carreras ,  Noah Bell

IPC分类号： A01N43/42 ,  A61K31/47 ,  C07D217/00 ,  C07D217/02

CPC分类号： A61K31/4725 ,  A61K31/18 ,  A61K31/472 ,  A61K31/517 ,  A61K31/662 ,  A61K31/675 ,  A61K45/06 ,  A61K47/55 ,  A61P1/00 ,  A61P7/10 ,  A61P9/04 ,  A61P9/12 ,  C07C311/29 ,  C07D215/14 ,  C07D217/04 ,  C07D217/14 ,  C07D217/16 ,  C07D401/12 ,  C07F9/3808 ,  C07F9/3834 ,  C07F9/3882 ,  C07F9/5765 ,  C07F9/60 ,  C07F9/65583

摘要： The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

摘要翻译： 本公开涉及用于治疗与流体保留或盐过载相关的疾病的化合物和方法，例如心力衰竭（特别是充血性心力衰竭），慢性肾脏疾病，终末期肾病，肝脏疾病和过氧化物酶体 增殖激活受体（PPAR）γ激动剂诱导的液体保留。 本公开还涉及用于治疗高血压的化合物和方法。 本公开还涉及用于治疗胃肠道疾病的化合物和方法，包括治疗或减少与胃肠道疾病相关的疼痛。

公开(公告)号：US20120263670A1

公开(公告)日：2012-10-18

申请号：US13172394

申请日：2011-06-29

申请人： Dominique Charmot ,  Jeffrey W. Jacobs ,  Michael Robert Leadbetter ,  Marc Navre ,  Christopher Carreras ,  Noah Bell

发明人： Dominique Charmot ,  Jeffrey W. Jacobs ,  Michael Robert Leadbetter ,  Marc Navre ,  Christopher Carreras ,  Noah Bell

IPC分类号： A61K31/472 ,  A61K31/675 ,  C07D217/16 ,  C07D401/14 ,  A61K31/4725 ,  C07D295/155 ,  A61K31/495 ,  C07D403/10 ,  A61K31/506 ,  C08G73/04 ,  A61K31/795 ,  C08F26/06 ,  C08F20/58 ,  A61P9/04 ,  A61P13/12 ,  A61P1/16 ,  A61P9/12 ,  A61P1/00 ,  C07F9/62

CPC分类号： A61K31/4725 ,  A61K31/18 ,  A61K31/472 ,  A61K31/517 ,  A61K31/662 ,  A61K31/675 ,  A61K45/06 ,  A61K47/55 ,  A61P1/00 ,  A61P7/10 ,  A61P9/04 ,  A61P9/12 ,  C07C311/29 ,  C07D215/14 ,  C07D217/04 ,  C07D217/14 ,  C07D217/16 ,  C07D401/12 ,  C07F9/3808 ,  C07F9/3834 ,  C07F9/3882 ,  C07F9/5765 ,  C07F9/60 ,  C07F9/65583

摘要： The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

摘要翻译： 本公开涉及用于治疗与流体保留或盐过载相关的疾病的化合物和方法，例如心力衰竭（特别是充血性心力衰竭），慢性肾脏疾病，终末期肾病，肝脏疾病和过氧化物酶体 增殖激活受体（PPAR）γ激动剂诱导的液体保留。 本公开还涉及用于治疗高血压的化合物和方法。 本公开还涉及用于治疗胃肠道疾病的化合物和方法，包括治疗或减少与胃肠道疾病相关的疼痛。